Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Basic Physician Training Written Prep > Rheumatology > Flashcards

Rheumatology Flashcards

1
Q

Anti DNA Topoisomerase I / Scl-70

A

Diffuse Cutaneous Systemic Sclerosis dcSSc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anti-Centromere Ab (ACA)

A

Limited Cutaneous Systemic Sclerosis (lcSSc)
- only 5% of patients with dcSSc will be positive for ACA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Anti-RNA Polymerase III

A

If present in patients with dcSSc is associated with rapidly progressive skin involvement and high risk for renal crisis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Classification of Inflammatory Myopathies

A

Idiopathic Inflammatory Myopathies:
- Polymyositis, Dermatomyositis with the subsets of Anti-Synthetase syndrome and Amyopathic Dermatomyositis (Anti MDA)

Immune Mediated necrotizing myopathy:
- Anti SRP and anti-HMGcoR

Inclusion Body Myositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Classification of Inflammatory Myopathies

A

Idiopathic Inflammatory Myopathies:
- Polymyositis, Dermatomyositis with the subsets of Anti-Synthetase syndrome and Amyopathic Dermatomyositis (Anti MDA)

Immune Mediated necrotizing myopathy:
- Anti SRP and anti-HMGcoR

Inclusion Body Myositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Polymyositis

A

By far the rarest form of myositis (5%)

Timeline: Subacute (weeks)
Clinical Features:
- proxima, symmetrical
Extra-Muscular:
- Lung - NSIP
- Heart - pericarditis, conduction block
- Oesophageal dysmotility

10-50 fold CK
No specific serology

Good response to immunosupression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Dermatomyositis

A

Subacute (weeks)
Similar pattern to PM.
Cutaneous findings:
- Gottron papules
- Heliotrope Rash
- V and Shawl Sign

Extra-muscular:
- ILD more common (20-25%)
- Cardiac - CHB, pericarditis

CK 10-15 fold
Anti-Mi2 Ab (good treatment response)
Anti-MDA5 (Rapidly progressive ILD)
Associated with malignancy (poor prognosis)

Good response to treatment apart from ILD or malignancy associated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Immune mediated Necrotising Myositis

A

Rapidly progressive, acute presentation
Symmetrical, proximal
May be seen after statin exposure, but different to common statin induced myopathy.

CK 10-50 fold elevated
Anti-SRP Ab
Anti-HMGCR

Biopsy: Necrosis without inflammation

Immunosuppression, escalation in therapy may be needed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Inclusion body myositis

A

Slowly progressive over years
Asymmetrical
Proximal + long finger extensors + knee extensors + dysphagia (cricopharyngeal)

CK only 10-15 fold

Male > Female
>50 years
cN1A Ab

Biopsy: “invasion” of muscle fibres, amyloid deposition

Slowly progressive, wheelchair within 10-15 years
Does not respond to Immunosuppression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Anticentromere Ab

A

90% of LcSSc, associated with risk of PAH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Anti-Scl 70 (DNA topoisomerase 1)

A

dcSSc, risk of ILD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Anti-RNA Pol III

A

DcSSc, associated with rapidly progressive skin disease and high risk of scleroderma renal crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anti-U3-RNP

A

dcSSc, associated with poor outcome and skeletal involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pattern of arthritis is SSc

A

12-60% of patients with SSc will have joint involvement.
- Hand and wrist predominance, often affects DIP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Significance of tendon friction rubs

A

Can be felt or heard over a tendon, indicator of active disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Raynauds Phenomonon

A

Occurs in 95% of SSc.
Earliest manifestation
If you have Raynauds, an associated SSc Ab and nailfold capillary changes - 80% chance of developing SSc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Scleroderma Renal Crisis:

A

5% of patients.
Anti-RNA Pol III gives increased risk
Use of glucocorticoids gives increased risk

Clinical: Hypertensive crisis

Tests: Micro-angiopathic haemolytic anaemia.

Tx: ACE inhibitor to control BP (captopril), continue even in the setting of rising Cr and dialysis as late improvement may occur.
Prophylaxis: Calcium channel blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Lung Involvement:

A

ILD in 50% of patients with dcSSc (85% if anti Scl 70 positive)
Pattern: NSIP > UIP
Tx: Nintedanib now approved for SSc with ILD

PAH in 10% of patients (more likely in anti-centromere +ve lcSSc
- WHO Group 1 with function class II-iV can have treatment with vasodilating therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Anti-HMG Co-R AB

A

Immune mediated Necrotising myopathy
- Severe myopathy
- no extra-muscular involvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatment of PAH

A

Endothelin R antagonists:
- Bosentan, Ambrisentan (selective)
- Macitentan (non-selective)

PDE-5 Inhibitors
- Sildenafil, Tadalafil

Riociguat

Prostatcycline antagnosist
- iloprost, epoprosteonol

Combination therapy with ambrisentan and tadalafil better than mono-therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Anti-Jo 1

A

Anti-synthetase Syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Anti-Mi2

A

Classical Dermatomyositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Anti-MDA5

A

DM with rapidly progressive ILD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Anti-SRP

A

Immune mediated Necrotising myopathy
- Severe myopathy
- no extra-muscular involvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Mixed Connective Tissue Disease
Features of at least 2 of: - SLE, Polymyositis, SSc Positive anti-U1-ribonucleoprotein (anti-U1-RNP)
24
Spondyloarthpropathies
Axial Spondyloarthropathies: - Non-Radiographic SpA - Radiographic SpA = Ankylosing Spondylitis Peripheral Spondyloarthropathies: - Reactive Arthritis - Psoriatic Arthritis - Enteric or IBD associated arthritis
25
Pathophysiology of Spondyloarthropathies
T cell Activation with Th17 phenotypes - TNF-Alpha - IL1, IL-17, IL23 Enthesitis --> bone erosion -->new bone formation. Causing boney proliferation and destruction.
26
HLAB27
Found in 6% of northern europeans. Only 5% of those carrying it will develop at SpA, and not all those with SpA have it. Sensitivity varies: - 95% in AnkSpon - 50-75% on IBD-Arthritis -
27
Ankylosing Spondylitis Peripheral
Enthesitis Asymmetical, Large joint Oligoarthritis (hips, shoulders) Dactylitis uncommon
28
Ankylosing Spondylitis Extraarticular manifestations
Opthal: Anterior Uveitis (unilateral, recurrent) Cardiovascular: Aortic valve disease (regurgitation), conduction disease Pulmonary: Restrictive lung disease, rarely apical lung fibrosis Bone: High risk of vertebral fractures
29
Psoriatic Arthritis
Occurs in 10-40% of patients with psoriasis. Skin psoriasis occurs first or co-occurs in 90%. therefore 10% of cases occur before skin (up to 10 years in advance) No correlation between extent of joint involvement and severity of skin disease. Nail involvement (pitting and onycholysis) is a risk factor for joint disease. 5 patterns: - symmetrical polyarthritis - asymetrical oligoarthritis - DIP predominant - spondyloarthritis - arthritis mutilans
30
Psoriatic Extra-articular manifestations
Opthal: Conjunctivitis more common than uveitis Skin and nail changes
31
IBD Associated Arthritis
4-46% of patients with IBD. 3 patterns: - Sacroilitis (most common), strongly associated with HLAB27, not related to bowel flare. - Acute polyarticular peripheral arthritis, knees most commonly involved, may parallel exacerbations of bowel disease. - Chronic polyarticular peripheral arthritis, less than 5%, not correlated with bowel activity.
32
Reactive Arthritis
Occurs within 2 weeks following certain GI or GU infections. Chlamydia trachomatis, Ureaplasma urealyticum in the urethra. Campylobacter, E Coli, Salmonella, Shigella and Yersinia in the intestine. Asymmetrical monoarticular or oligoarticular. - Knee, ankle and wrist most common Enthesitis very common 90% - achilles tendonitis or plantar fasciitis.
33
Management of axial spondyloarthritis
Physical Therapy NSAIDs Anti-TNF: Infliximab, Adalinumab, Golimumab, Certolizumab, Etenercept IL-17A inhibitors: Secukinumab, Ixekizumab JAKi: Upadacitib DMARDS for peripheral arthritis: Sulfasalazine and Methotrexate. All have RCT evidence of both radiographic SpA and non-radiographic SpA. No head to head studies, choice depend on patient factors.
34
Role of non-biological DMARDS like methotrexate in Ank Spon?
These is NO ROLE in axial arthritis, and does have some role in peripheral arthritis.
35
Diagnostic Criteria for Ank Spon
New York Criteria: Clinical: - Restriction in lateral or forward flexion of spine - reduced chest expansion - Inflammatory lower back pain > 3 months Radiological: - Bilateral grade 4 sacro-ilitis on XR - Unilater grade 3-4 sacro-illitis on XR BUT this is now old, terminology is now "axial spondyloarthritis" which is split into radiographic and non-radiographic.
36
IL-17A Therapy
Secukinumab and Ixekizumab: Increased risk of UNcomplicated fungal infections (candida)
37
JAK Inhibitor therapy for SpA
Upadacitinib - Selective JAK inhibitor (JAK1, JAK3, less JAK2) Risk of viral infection esp Herpes Zoster
38
Diagnosis of Psoriatic Arthritis
1 - Presence of MSK inflammtation (either peripheral arthritis, axial arthritis or enthesitis) 2 - Plus: - Skin psoriasis - Family history of psoriasis - Dactylitis - Nail changes (pitting, onycholysis) - RF negative - Evidence of juxta-articular bone formation f XR
39
Treatment options in psoriatic arthritis
NSAIDs and Physical Therapy - Symptom benefit Local Corticosteroid injections for peripheral arthritis. csDMARD: Sulfasalazine, MTX, Leflunamide. Not for axial disease. Anti- TNF Anti IL17A: Secukinumab, Ixekizumab anti- IL12/23: Ustekinumab (p40 subunit) JAK1/3i: Tofacitinib anti-IL 23: Guselkumab (p19 subunit)
40
Comparison of antiTNF Adalinumab with antiIL17A (Secukinumab, Ixekizumab)
Similar results for arthritis. Anti-IL17A superior for skin.
41
Is there a role for co-prescription of csDMARD and biologic DMARD?
No. SEAM Trial. TNF mono-therapy as effective as TNF + MTX.
42
Giant Cell arteritis epidemiology
Female>male. Peak age 70-79 (80% of patients are > 70) Association with HLA DRB1*04 Association with PMR: - 50% of GCA will have PMR sx - 10-15% of PMR will get GCA as some point.
43
How to differentiate between CRAO and NAAION
Both present in older people with vascular risk factors. Both present with acute monocular vision loss. On exam : Both will have RAPD. The differentiation is on fundoscopic examination: - NAAION will show optic disc swelling - CRAO will show cherry red spot Management: - NAAION, vascular risk factor management and exclude AAION - CRAO - this is a stroke, work up and manage as per stroke
44
Imaging in GCA
TA US: Halo sign has 90% specificity, 70% sensitivity. -Useful for ruling out those with low pre test probability CTA/MRI/PET may be considered to assess for large vessel involvement.
45
GCA management
No visual sx --> PO steroids Visual sx --> IV MP 3 days then PO
46
GiACTA Study for GCA
Tocilizumab with steroids resulted in
47
ANCA vasculitis - GPA vs MPA relapse rate?
Regardless of the clinical presentation - PR3 positive disease is more likely to relapse than MPO positive disease.
48
CYCLOPS TRIAL
For treatment of ANCA Vasculitis: PO and IV Ciclophosphamide are equivalent
49
RAVE Study
For treatment of severe GPA/MPA Rituximab induction vs PO Cyclophosphamide Induction Rituximab non-inferior to cyclophosphamide - many would choose rituximab due to better side effect protocol.
50
Role of PLEX in ANCA associated vasculitis?
PEXIVAS Trial showed no benefit of PLEX for treatment of severe GPA/MPA including in the subset of people with pulmonary haemorrhage. PLEX MAY have a role in: - Double positive ANCA Anti-GBM disease - Severe renal impairment (controversial) - Severe pulmonary haemorrhage (contraversial)
51
Avacopan
Avacopan is a C5a Receptor inhibitor. ADVOCATE trial compared Avacopan vs prednisolone taper in ANCA associated vasculitis. Avacopan was non-inferior to PNL at 26 weeks and superior to PNL at 52 weeks.
52
Treatment of non-Severe MPA/GPA?
Methotrexate + low dose pred
53
Remission maintenance for MPA/GPA?
Relapse is common, more common with PR3+ than MPO+ Traditionally Aza, MTX, Cyclophosphamide used. Rituximab 6 monthly infusions is superior for remission maintenance.
54
Remission maintenance for MPA/GPA?
Relapse is common, more common with PR3+ than MPO+ Traditionally Aza, MTX, Cyclophosphamide used. Rituximab 6 monthly infusions is superior for remission maintenance.
55
Treatment of EGPA?
Can be ANCA negative or ANCA MPO positive (is almost never PR3 positive) Mepolizumab (Anti-IL5) is superior to placebo but prognosis is still poor.
56
Rheumatoid Arthritis HLA
Shared epitope = a 5 amino acid sequence commonly encoded by the HLA DR locus, especially HLA-DRB1*01 and HLA-DRB1*04
57
Risk factors for RA
HLA DRB1*01/04 STAT4 PADI PTPN22 Smoking Periodontitis Gut dysbiosis Anti-CCP
58
Key Cytokines in RA
IL-1, IL-6, TNF
59
Key Cell in RA
MAcrophage, T cell, B cell PMN is the most abundant cell in the synovial fluid
60
XR features of RA
Joint space narrowing subchondral osteopenia DIP sparing
61
Rheumatoid factor
Ab against Fc portion of IgG Utility in RA - RF positive disease is associated with more rheumatoid nodules, vasculitis, and worse prognosis. Highly associated with RA, Sjogren Syndrome, Cryoglobulinaemia. Also seen in non-rheumatic disease: - Hepatitis B and C - Endocarditis - Viral infection - Other chronic infections
62
AntiCCP/ACPA
High specific for RA (90%) Predictive or developing RA in asymptomatic and early undifferentiated arthritis. Sensitivity 70% Marker of severe and erosive disease.
63
Methotrexate MOA
Inhibits purine (adenine and guanine) nucleotide synthesis by inhibition of enzyme dyhydrofolate reductase (DHF).
64
Methotrexate adverse effects?
Pancytopenia Liver Transaminitis Pneumonitis Give Folinic Acid rescue if sepsis + leukopenia
65
Leflunomide MOA
Inhibits pyrimidine (cytosine, thymine, uracil) synthesis.
66
Leflunomide adverse effects?
Pancytopenia, transaminitis, pneumonitis. Cholestyramine rescue if sepsis and leucopenia.
66
Leflunomide adverse effects?
Pancytopenia, transaminitis, pneumonitis, diarrhoea Cholestyramine rescue if sepsis and leucopenia.
67
Methotrexate and Leflunomide
Think of the two as brothers: MTX - purine synthesis LFN - Pyrimidine synthesis Same side effect profile, but LFN more likely to cause diarrhoea. Rescue if sepsis and leukopenia: - MTX - Folinic Acid - LFN - Cholestyramine binds LFN
68
Etanercept
Anti TNF however is a soluble TNF receptor - structurally it is a Fc portion of human Ig fused to a TNF receptor. Weekly subcut injection, shorter halflife of 4 days.
69
Infliximab vs Adalinumab
Infliximab is a chimeric (75% humanised, 25% murine) mAb, Adalinumab is 100 humanised mAb. Infliximab has halflife of 10 days and is given IV 8 weekly Adalinumab has a halflife of 14 days and is given sub cut fornightly.
70
Precautions for TNF blockade?
TB Congestive heart failure Demyelinating disease Lymphoma Lupus like syndrome of ANA/dsDNA positive Cancer in last 5 years
71
Adverse effects of TNF blockage?
Infections (normal bacterial) Herpes Zoster Chronic HSV (ophthalmic) Melanoma
72
Immunosuppression drugs and risk of skin cancer?
TNF blockage - melanoma Thiopurines - non-melanoma SC
73
Management of TB if wanting to start anti-TNF?
Latent TB: - Isoniazid for 4-6 weeks before starting TNF, and continue for 9 months treatment. - Latent TB is not a contraindication to anti-TNF - liver enzyme derangement is a common problem with isoniazid Active TB: - Treat with standard therapy RIPE - Should have at least 2 months treatment by a TB speciality prior to anti-TNF therapy
74
Tocilizumab
iL-6R mAb (Blockage) A/E: - LFT derangement, especially in combo with MTX - Increased total and HDL(but decreased CRP leads to decreased CVS risk) - Diverticular perforation (rare)
75
Rituximab
-imab (chimeric Ab) IV Infusion 90% of B cells depleted in 3 months (measure CD 19+ levels) Does not deplete early pre-B cells or Plasma cells, therefore no fall in Ig initially. B cells are restored between 6-18 months later.
76
Abatacept
CTLA-Ig fusion protein, therefore it acts as CTLA would do. Binds to B7 (CD80/86) on APC and prevents B7 binding to CD28 (co-stimulation). This is opposite to the effect of Anti-CTLA4 mAb used in cancer immunotherapy.
77
Tofacitinib
Inhibits Jak 1 and Jak 3 Blocking the JAK-STAT pathway will block signalling of multiple cytokines, therefore these are more immunosuppression than IL inhibitors. Risk of herpes zoster reactivation. Give shingrix vaccine. Other JAK inhibitors: - Bari (JAK 1/2) - Tofa (JAK1/3) - Upa (JAK1) more selective
78
RA in pregnancy:
Methotrexate - cease >6 weeks prior to conception, cannot use if breastfeeding (same for leflunamide - brothers) Sulfasalazine, low dose pred, and Aza are all safe to continue. - remember small increase risk of cleft lip with prednisolone. Certalizumab does not cross placenta and therefore can be used. - other anti-TNF cannot be used.
79
Management of RA drugs peri-operatively:
csDMARDs can be continued through the peri-operative period. bDMARDs should be held. Schedule surgery at the end of the dosing interval for that medication and hold until external wound healing is complete (usually 2 weeks) JAKi - hold for 3 days pre-operatively .
80
Perioperative management of patients on glucocorticoids:
HPA suppressed = >20mg prednisolone for 3 weeks, or cushingoid appearance. Intermediate HPA suppressed = between 5-15mg prednisolone for > 3 weeks. Need to do AM cortisol and then ACTH testing to assess HPA axis. HPA non-suppressed = Any dose of steroid for <3 weeks, or <5mg day doses for any duration. These patients will not be HPA suppressed.
80
Perioperative management of patients on glucocorticoids:
HPA suppressed = >20mg prednisolone for 3 weeks, or cushingoid appearance. Intermediate HPA suppressed = between 5-15mg prednisolone for > 3 weeks. Need to do AM cortisol and then ACTH testing to assess HPA axis. HPA non-suppressed = Any dose of steroid for <3 weeks, or <5mg day doses for any duration. These patients will not be HPA suppressed.
81
Urate lowering therapy
Allopurinol - Competitive inhibitor of XO - Risk of DRESS with HLAB 5801 (common in Han Chinese) Febuxostat - non-competitive inhibitor - Use in Han Chinese - Increased risk of cardiovascular events

Basic Physician Training Written Prep (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions